Michael Rogers
Directeur/Membre du Conseil chez AKEBIA THERAPEUTICS, INC.
Fortune : 141 152 $ au 31/05/2024
Postes actifs de Michael Rogers
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 12/12/2018 | - |
| Independent Dir/Board Member | 12/12/2018 | - |
Historique de carrière de Michael Rogers
Anciens postes connus de Michael Rogers
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ARAVIVE, INC. | Directeur/Membre du Conseil | 15/09/2020 | 17/01/2024 |
| Independent Dir/Board Member | 15/09/2020 | 17/01/2024 | |
| AERPIO PHARMACEUTICALS | Comptroller/Controller/Auditor | 15/11/2017 | 15/10/2019 |
| Directeur Financier/CFO | 15/11/2017 | 15/10/2019 | |
| Investor Relations Contact | 15/11/2017 | 15/10/2019 | |
| Public Communications Contact | 15/11/2017 | 15/10/2019 | |
| Corporate Officer/Principal | 14/05/2019 | 15/10/2019 | |
| EYEPOINT PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/01/2005 | 01/06/2019 |
| Independent Dir/Board Member | 01/01/2005 | 01/06/2019 | |
| KERYX BIOPHARMACEUTICALS | Directeur/Membre du Conseil | 01/04/2016 | 13/09/2017 |
| Président | 11/09/2017 | 12/12/2018 | |
| Independent Dir/Board Member | 01/04/2016 | 12/12/2018 | |
| ACORDA THERAPEUTICS, INC. | Directeur Financier/CFO | 07/10/2013 | 04/10/2016 |
| FORTRESS BIOTECH, INC. | Directeur/Membre du Conseil | 22/09/2011 | 26/12/2013 |
| Independent Dir/Board Member | 01/05/2011 | 26/12/2013 | |
| BG MEDICINE, INC. | Directeur Financier/CFO | 14/10/2009 | 18/10/2012 |
| Treasurer | 28/03/2011 | 18/10/2012 | |
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Directeur Financier/CFO | 01/02/1999 | 01/04/2009 |
| Treasurer | 01/02/1999 | 01/04/2009 | |
| ░░░ ░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
Formation de Michael Rogers
| Union College (New York) | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 17 |
Opérationnelle
| Director of Finance/CFO | 7 |
| Director/Board Member | 5 |
| Independent Dir/Board Member | 5 |
Sectorielle
| Health Technology | 12 |
| Finance | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| EYEPOINT PHARMACEUTICALS, INC. | Health Technology |
| BG MEDICINE, INC. | Health Technology |
| FORTRESS BIOTECH, INC. | Health Technology |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| ARAVIVE, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
AutoImmune, Inc.
 AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Health Technology |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
AHT Corp.
 AHT Corp. Services to the Health IndustryHealth Services AHT Corp. is a national provider of Internet-based clinical e-commerce among physicians, other healthcare provides and healthcare organizations. The company is focused on automating laboratory and prescription transactions. Its products principally focus on laboratory and prescription connectivity and transaction processing, including within the laboratory suite of applications, Dr. Chart (R), Dr. Chart Web (TM), Compliance Monitor (TM), CDR (TM) and CDM (TM) and its electronic prescription writing product.. The company was founded by Edelson Jonathan on June 20, 1995 and is headquartered in Tarrytown, NY. | Health Services |
| PaineWebber, Inc. | Finance |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Apnimed, Inc.
 Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Michael Rogers
- Expérience
